{"id":"yf-vaccine-live","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Headache"},{"rate":"10-30","effect":"Myalgia"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Injection site reaction"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine contains a weakened strain of yellow fever virus (17D strain) that replicates in vaccinated individuals but does not cause disease in immunocompetent hosts. This replication triggers robust antibody production and T-cell mediated immunity, conferring long-lasting protection against natural yellow fever virus infection. A single dose typically provides lifelong immunity in most recipients.","oneSentence":"YF vaccine (live) is a live attenuated yellow fever virus vaccine that stimulates both humoral and cellular immune responses to provide protection against yellow fever infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:11.856Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas"}]},"trialDetails":[{"nctId":"NCT07103148","phase":"PHASE3","title":"A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-07-11","conditions":"Yellow Fever Immunization","enrollment":2440},{"nctId":"NCT02743455","phase":"PHASE1","title":"A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-07-05","conditions":"Yellow Fever, Yellow Fever Immunisation","enrollment":92},{"nctId":"NCT07002060","phase":"PHASE3","title":"Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-05-22","conditions":"Yellow Fever Immunization","enrollment":640},{"nctId":"NCT06399003","phase":"PHASE3","title":"Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-06-28","conditions":"Measles-Mumps-Rubella","enrollment":1200},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT05801978","phase":"PHASE4","title":"Durability of Vaccine Responses","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-11","conditions":"Vaccine Response","enrollment":66},{"nctId":"NCT05421611","phase":"PHASE3","title":"A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2023-05-11","conditions":"Yellow Fever","enrollment":1824},{"nctId":"NCT06815835","phase":"PHASE3","title":"Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-04-01","conditions":"Measles, Rubella, Yellow Fever","enrollment":1530},{"nctId":"NCT02963909","phase":"PHASE1","title":"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-01","conditions":"Zika Virus Infection","enrollment":75},{"nctId":"NCT05447377","phase":"PHASE3","title":"A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants","status":"UNKNOWN","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2022-09-16","conditions":"Yellow Fever","enrollment":2216},{"nctId":"NCT01488890","phase":"PHASE2","title":"Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-12-06","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":390},{"nctId":"NCT02699099","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-10","conditions":"Malaria, Malaria Vaccines","enrollment":699},{"nctId":"NCT02710045","phase":"NA","title":"The Interaction Between Measles and DTP Vaccination","status":"COMPLETED","sponsor":"Medical Research Council Unit, The Gambia","startDate":"2007-11","conditions":"Non-target Heterologous Effects of Vaccines, Vaccine Interactions","enrollment":302},{"nctId":"NCT00254826","phase":"PHASE1","title":"Yellow Fever Virus Vaccine and Immune Globulin Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2006-06","conditions":"Viremia","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["YF-VAX vaccine","YF-VAX"],"phase":"phase_3","status":"active","brandName":"YF vaccine (live)","genericName":"YF vaccine (live)","companyName":"Sanofi","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"YF vaccine (live) is a live attenuated yellow fever virus vaccine that stimulates both humoral and cellular immune responses to provide protection against yellow fever infection. Used for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}